# Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

> **NCT03290794** · — · COMPLETED · sponsor: **Bayer** · enrollment: 100 (actual)

## Conditions studied

- Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** Aflibercept (Eylea, BAY86-5321)

## Key facts

- **NCT ID:** NCT03290794
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-14
- **Primary completion:** 2022-11-25
- **Final completion:** 2023-05-26
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03290794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03290794, "Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03290794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*